OmniAb (OABI) Insider Steven Crouse Sells 20,000 Shares
Insider Steven Crouse sold 20,000 shares of OmniAb, valued at about $46,800, on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Steven Crouse sold 20,000 shares of OmniAb, Inc. ($OABI) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OABI is up 12.3% after 1 week, up 4.4% after 1 month and up 126.1% to date (from the $2.03 close on Jun 17, 2026).
OABI
OmniAb, Inc.
Key Points
- Steven Crouse sold 20,000 shares of OmniAb, Inc. on June 17, 2026, at a price of $2.34 per share, totaling about $46,800.
- The stock is currently trading at $2.34, significantly below its 52-week high of $5.43, which raises questions about recent insider activity.
- Analysts maintain a positive outlook with a target mean price of $8.4 based on five opinions, reflecting confidence in the company's future.
Get $OABI trade alerts by text
We text you when insiders, Congress or big funds trade $OABI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated OmniAb, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at OmniAb, Inc.
On June 17, 2026, Steven Crouse sold 20,000 shares of OmniAb, Inc. (OABI) at a price of $2.34 per share. This sale totaled approximately $46,800. Crouse's transaction is part of a broader trend of insider trading on this day, as multiple insiders also sold shares.
Other Insiders Follow Suit
Alongside Crouse, other insiders at OmniAb also sold 20,000 shares each on the same day. Steven Love, Philip Gotwals, and John Higgins each executed similar sales, reflecting a common pattern among the company's insiders. Notably, Steven Love and Philip Gotwals also made purchases of 40,000 and 20,000 shares, respectively, on June 17, 2026, suggesting mixed signals within the management team regarding the company's stock.
How OmniAb, Inc. Stock Has Traded
The shares of OmniAb are currently trading at $2.34, which is below the 50-day moving average of $3.38 and the 200-day moving average of $2.29. This price point is significantly lower than the stock's 52-week high of $5.43, indicating a challenging market environment for the company. Investors may view these insider sales in light of the stock's performance as they consider the implications for future growth.
Analysts Set New Price Targets
Analysts are generally optimistic about OmniAb, with several firms maintaining positive ratings. On October 7, 2026, Leerink Partners maintained its "Outperform" rating with a price target of $12.00, up from $10.00. StoneX also maintained a "Buy" rating, increasing its target from $4.00 to $6.00. HC Wainwright & Co. reiterated its "Buy" rating with a target of $11.00 on August 17, 2026. The consensus among analysts is a mean price target of $8.4, based on five opinions.
What OmniAb, Inc. Does
OmniAb, Inc. is a biotechnology company based in Emeryville, California. It focuses on providing antibody discovery technologies to pharmaceutical and biotech firms, enabling the development of new therapeutics. The recent insider trades may reflect strategic adjustments as the company navigates its market position.
What's Next for OmniAb
Investors will be watching for the next earnings report scheduled for November 4, 2026. The recent insider transactions reflect positions as of June 17, 2026, and may not represent current holdings. Further filings and updates from the company will be important to monitor as they could provide more insights into management's outlook and strategy.
Related Filing Alerts
Source: Steven Crouse's Form 4 filing on $OABI (Jun 17, 2026). Find the original filing: OABI Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts